PMID- 21873158
OWN - NLM
STAT- MEDLINE
DCOM- 20111101
LR  - 20111117
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 31
IP  - 7
DP  - 2011 Jul
TI  - Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 
      peptide vaccination.
PG  - 2447-52
AB  - BACKGROUND: The object of this study was to investigate the clinical predictive 
      capability of peripheral myeloid dendritic cells (DCs) in Wilms' tumor 1 (WT1) 
      vaccine therapy for patients with gynaecological cancer. PATIENTS AND METHODS: 
      Six patients with WT1/human leukocyte antigen (HLA)-A*2402-positive 
      gynaecological cancer were included in this study. The patients received 
      intradermal injections of a modified 9-mer WT1 peptide every week for 12 weeks. 
      Peripheral blood samples were obtained at 0, 4, 8 and 12 weeks after the initial 
      vaccination. Circulating DCs were detected by flow cytometry. RESULTS: The 
      frequencies of CD14(+)CD16(+)CD33(+)CD85(+) myeloid DCs were significantly higher 
      in the therapeutically effective group than in therapeutically inert group 
      (p<0.05). CONCLUSION: These results suggested that myeloid DCs, which should be 
      associated with inducing cytotoxic T-cells, provided additional prognostic 
      information in the use of cancer peptide vaccine.
FAU - Ohno, Satoshi
AU  - Ohno S
AD  - Consolidated Research Institute for Advanced Science and Medical Care, Waseda 
      University, 513, Wasedatsurumaki-cho, Shinjuku-ku, Tokyo 162-0041, Japan. 
      satoshi.ohno55@gmail.com
FAU - Takano, Fumihide
AU  - Takano F
FAU - Ohta, Yasuyuki
AU  - Ohta Y
FAU - Kyo, Satoru
AU  - Kyo S
FAU - Myojo, Subaru
AU  - Myojo S
FAU - Dohi, Satoshi
AU  - Dohi S
FAU - Sugiyama, Haruo
AU  - Sugiyama H
FAU - Ohta, Tomihisa
AU  - Ohta T
FAU - Inoue, Masaki
AU  - Inoue M
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A*24:02 antigen)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Peptide Fragments)
RN  - 0 (Vaccines, Subunit)
RN  - 0 (WT1 Proteins)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Adult
MH  - *Blood Cell Count
MH  - Cancer Vaccines/*immunology
MH  - Combined Modality Therapy
MH  - *Dendritic Cells
MH  - Female
MH  - Flow Cytometry
MH  - Genital Neoplasms, Female/*blood/drug therapy/immunology/surgery/therapy
MH  - HLA-A Antigens/administration & dosage/immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Immunization Schedule
MH  - Immunologic Surveillance
MH  - Immunophenotyping
MH  - *Immunotherapy, Active
MH  - Injections, Intradermal
MH  - Middle Aged
MH  - Peptide Fragments/administration & dosage/immunology
MH  - Treatment Outcome
MH  - Tumor Burden
MH  - Vaccines, Subunit/immunology
MH  - WT1 Proteins/administration & dosage/*immunology
EDAT- 2011/08/30 06:00
MHDA- 2011/11/02 06:00
CRDT- 2011/08/30 06:00
PHST- 2011/08/30 06:00 [entrez]
PHST- 2011/08/30 06:00 [pubmed]
PHST- 2011/11/02 06:00 [medline]
AID - 31/7/2447 [pii]
PST - ppublish
SO  - Anticancer Res. 2011 Jul;31(7):2447-52.